Thanks. It would be interesting to know if Credit Suisse concurs with any of IPIX's assertions. If you have a Schwab account you can read a lot more about their assessment of Galera and their drugs. They initiated coverage at Neutral, btw.
See "GRTX: Initiate at Neutral: Compelling clinical data, challenging commercialization path" in the Rating's Summary section of the GTRX quote page.